Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 11/20 | 0.72 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.72 |
| ▸ | JAK1 | P23458 | 3/20 | 0.49 |
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 2/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4833993 | 0.89 | TBK1 (0.79) | TBK1IKBKEJAK1ACHEADORA3 | |
| SCHEMBL4842227 | 0.85 | TBK1 (0.73) | TBK1IKBKEJAK1ACHEADORA3 | |
| SCHEMBL4843679 | 0.85 | TBK1 (0.78) | TBK1IKBKEJAK1ACHEADORA3 | |
| SCHEMBL4846026 | 0.84 | TBK1 (1.00) | TBK1IKBKEJAK1ACHEADORA3 | |
| SCHEMBL6250046 | 0.84 | TBK1 (0.77) | TBK1IKBKEJAK1ACHEADORA3 | |
| SCHEMBL4834234 | 0.84 | TBK1 (0.73) | TBK1IKBKEJAK1ACHEADORA3 | |
| SCHEMBL4839205 | 0.83 | TBK1 (0.75) | TBK1IKBKEJAK1ACHEADORA3 | |
| SCHEMBL4834654 | 0.82 | TBK1 (0.73) | TBK1IKBKEJAK1ACHEADORA3 | |
| SCHEMBL4840443 | 0.82 | TBK1 (0.73) | TBK1IKBKEJAK1ACHEADORA3 | |
| SCHEMBL4842152 | 0.82 | TBK1 (0.73) | TBK1IKBKEJAK1ACHEADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539759-B1 | NOVEL IMIDAZOPYRIDINES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-08-15 | — | — | EP | claimed |
| US-7410966-B2 | Use of and some novel imidazopyridines | ASTRAZENECA AB (SE) | 2008-08-12 | — | — | US | disclosed |
| EP-1539759-B1 | NOVEL IMIDAZOPYRIDINES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-08-15 | — | — | EP | disclosed |
| US-20050261333-A1 | Use of and some novel imidazopyridines | ASTRAZENECA A B (SE) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261333-A1 | Use of and some novel imidazopyridines | ITK, CSNK1A1, RPS6KA1 | TBK1 1029/4885IKBKE 95/4885JAK1 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.